

CITATION REPORT

List of articles citing

Function of opioids in the enteric nervous system

DOI: 10.1111/j.1743-3150.2004.00554.x

Neurogastroenterology and Motility, 2004, 16 Suppl 2, 17-28.

Source: <https://exaly.com/paper-pdf/36784519/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
304	Nociception: basic principles. 2001 , 3-22		
303	Preclinical studies of opioids and opioid antagonists on gastrointestinal function. <i>Neurogastroenterology and Motility</i> , 2004 , 16 Suppl 2, 46-53	4	80
302	Alvimopan, a selective peripherally acting mu-opioid antagonist. <i>Neurogastroenterology and Motility</i> , 2005 , 17, 157-65	4	70
301	Basic and clinical pharmacology of new motility promoting agents. <i>Neurogastroenterology and Motility</i> , 2005 , 17, 643-53	4	109
300	Review article: endocannabinoids and their receptors in the enteric nervous system. 2005 , 22, 667-83		120
299	mu-Opiate receptor agonist loperamide blocks bethanechol-induced gallbladder contraction, despite higher cholecystokinin plasma levels in man. <i>Neurogastroenterology and Motility</i> , 2005 , 17, 761-64		3
298	Avoiding the vicious cycle of prolonged opioid use in Crohn's disease. 2005 , 100, 2230-2		21
297	Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized clinical trial. 2005 , 6, 184-92		133
296	Alvimopan for the management of postoperative ileus. 2005 , 39, 1502-10		38
295	Opioids, the Enteric Nervous System, and Postoperative Ileus. 2005 , 16, 188-196		7
294	Opioid receptor signaling: relevance for gastrointestinal therapy. 2006 , 6, 559-63		35
293	The enteric purinergic P2Y1 receptor. 2006 , 6, 564-70		30
292	Mechanisms and Consequences of Intestinal Inflammation. 2006 , 1115-1135		
291	Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients. 2006 , 12, 295-302		16
290	The hallucinogenic herb <i>Salvia divinorum</i> and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. <i>Neurogastroenterology and Motility</i> , 2006 , 18, 69-75	4	47
289	Ileal brake: neuropeptidergic control of intestinal transit. 2006 , 8, 367-73		103
288	Peripheral opioids for functional GI disease: a reappraisal. 2006 , 24, 91-8		10

287	Promotility medications--now and in the future. 2006 , 24, 297-307	53
286	Evaluation of the effects of the opioid agonist morphine on gastrointestinal tract function in horses. 2006 , 67, 992-7	114
285	Treatment of opioid-induced gut dysfunction. 2007 , 16, 181-94	78
284	Food-derived bioactive peptides influence gut function. 2007 , 17 Suppl, S5-22	25
283	Peripherally restricted μ -opioid receptor antagonists: a review. 2007 , 11, 27-32	5
282	The narcotic bowel syndrome: clinical features, pathophysiology, and management. 2007 , 5, 1126-39; quiz 1121-2	172
281	Irritable Bowel Syndrome. 2007 , 643-670	
280	Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. 2007 , 61, 1181-7	241
279	Fast-track surgery in laparoscopic radical prostatectomy: basic principles. 2007 , 25, 185-91	53
278	Epidural administration of morphine facilitates time of appearance of first gastric interdigestive migrating complex in dogs with paralytic ileus after open abdominal surgery. 2007 , 11, 648-54	10
277	Inhibitory effect of salvinorin A, from <i>Salvia divinorum</i> , on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. 2008 , 155, 681-9	68
276	Effect of gluten-free diet on preventing recurrence of gastroesophageal reflux disease-related symptoms in adult celiac patients with nonerosive reflux disease. 2008 , 23, 1368-72	12
275	Morphine, opioids, and the feline pulmonary vascular bed. 2008 , 52, 931-7	15
274	Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. 2008 , 27, 1122-31	23
273	Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. 2008 , 28, 312-25	107
272	Effects of serotonin 5-HT ₃ receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. <i>Neurogastroenterology and Motility</i> , 2008 , 20, 557-65	4 41
271	Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. 2008 , 27, 25-41	66
270	Opioid-induced bowel dysfunction. 2008 , 35, 103-13	72

269	The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. 2008 , 117, 162-87	57
268	Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. 2008 , 137, 428-440	112
267	Epidural analgesia and anesthesia in dogs and cats. 2008 , 38, 1205-30, v	91
266	Palliative care and pain: new strategies for managing opioid bowel dysfunction. 2008 , 11 Suppl 1, S1-19; quiz S21-2	25
265	Opioid side effects--mechanism-based therapy. 2008 , 358, 2400-2	37
264	Morphine tolerance in the mouse ileum and colon. 2008 , 327, 561-72	67
263	Methylnaltrexone for the management of unwanted peripheral opioid effects. 2008 , 5, 531-543	12
262	Methylnaltrexone in the treatment of opioid-induced constipation. 2008 , 1, 49-58	11
261	Epidural analgesia and gastrointestinal motility after open abdominal surgery--a review. 2008 , 44, 57-64	9
260	Safety and efficacy update: Alvimopan in postoperative ileus. 2009 , 1, CMT.S2384	1
259	Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness. 2009 , 3, 473-85	14
258	Methylnaltrexone. 2009 , 14, 679-82	1
257	Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. 2009 , 83, 10-7	67
256	Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. 2009 , 108, 1811-22	53
255	Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome. 2009 , 2, 169-181	8
254	Effect of oral naloxone hydrochloride on gastrointestinal transit in premature infants treated with morphine. 2009 , 98, 442-7	6
253	Opioidinduzierte Obstipation. Aktuelle Therapiemöglichkeiten in der palliativen Schmerztherapie. 2009 , 3, 18-21	
252	Cannabinoid signalling in the enteric nervous system. <i>Neurogastroenterology and Motility</i> , 2009 , 21, 899-902	16

251	Glucose, epithelium, and enteric nervous system: dialogue in the dark. 2009 , 93, 277-86	16
250	Opioid receptors in the gastrointestinal tract. 2009 , 155, 11-7	252
249	Pharmacotherapy of gastroparesis. 2009 , 10, 469-84	24
248	Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. 2009 , 12, 371-83	141
247	Constipation et traitements par les opioïdes. Physiopathologie et prise en charge. 2009 , 10, 171-177	
246	Enteric nervous system: sensory physiology, diarrhea and constipation. 2010 , 26, 102-8	36
245	In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure. 2005 , 37, 325-8	17
244	Antagonistes opioïdes et constipation. 2010 , 23, 182-188	
243	Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. 2010 , 55, 2912-21	113
242	Impact of gastric filling on radiation dose delivered to gastroesophageal junction tumors. 2010 , 77, 292-300	21
241	Opiate-induced oesophageal dysmotility. 2010 , 31, 601-6	102
240	The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. 2010 , 32, 884-93	33
239	The traditional antidiarrheal remedy, <i>Garcinia buchananii</i> stem bark extract, inhibits propulsive motility and fast synaptic potentials in the guinea pig distal colon. <i>Neurogastroenterology and Motility</i> , 2010 , 22, 1332-9	4 23
238	Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception. 2010 , 25, 1232-8	21
237	Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. 2010 , 334, 333-40	39
236	The effects of daikenchuto (DKT) on propulsive motility in the colon. 2010 , 164, 84-90	12
235	Met-enkephalins in patients with inflammatory bowel diseases. 2011 , 56, 158-64	20
234	Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. 2011 , 141, 982-991.e18	49

233	The Use of Rectus Sheath Catheters as an Analgesic Technique for Patients Undergoing Radical Cystectomy. 2011 , 4, 24-30	14
232	Enteric Nervous System: The Brain-in-the-Gut. 2011 , 3, 1-172	8
231	Opioid-induced constipation: challenges and therapeutic opportunities. 2011 , 106, 835-42; quiz 843	184
230	Endoscopic diagnosis of a pylorogastric intussusception with spontaneous resolution. 2011 , 47, e156-61	3
229	Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. 2011 , 56, 330-8	26
228	Validated tools for evaluating opioid-induced bowel dysfunction. 2011 , 28, 279-94	24
227	The opioid component of delayed gastrointestinal recovery after bowel resection. 2011 , 15, 1259-68	13
226	Direct induction of CCK and GLP-1 release from murine endocrine cells by intact dietary proteins. 2011 , 55, 476-84	67
225	Influence of intravenous opioid dose on postoperative ileus. 2011 , 45, 916-23	77
224	Recent Advances in Discovery and Development of Medicines for the Treatment of Secretory Diarrhea in the Developing World. 2011 , 277-300	
223	A pilot study of the nutritional status of opiate-using pregnant women on methadone maintenance therapy. 2012 , 47, 286-95	12
222	Fluid and Electrolyte Disturbances In Gastrointestinal and Pancreatic Disease. 2012 , 436-455	2
221	Clinical management of pain in advanced lung cancer. 2012 , 6, 331-46	29
220	Mechanisms and Consequences of Intestinal Inflammation. 2012 , 2075-2099	1
219	Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?. 2012 , 18, 6010-20	28
218	Agents that act luminally to treat diarrhoea and constipation. 2012 , 9, 661-74	40
217	Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/ μ opioid receptor antagonist. 2012 , 167, 1111-25	90
216	Opioid-induced bowel dysfunction: pathophysiology and management. 2012 , 72, 1847-65	144

215	How functional foods play critical roles in human health. 2012 , 1, 26-60	66
214	Cellular Neurophysiology of Enteric Neurons. 2012 , 629-669	10
213	Taming the Irritable Bowel. 2012 , 19, 142-156	
212	The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. 2012 , 16, 125-31	20
211	Prokinetics in diabetic gastroparesis. 2012 , 14, 297-305	13
210	The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. 2013 , 386, 479-91	10
209	Opioid Receptors as new target for insulin resistance. 2013 , 139, 334-40	16
208	Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. 2013 , 35, 1876-83	26
207	Opium use and risk of mortality from digestive diseases: a prospective cohort study. 2013 , 108, 1757-65	38
206	Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. 2013 , 27, 1564-71	17
205	Gastrointestinal physiology. 2013 , 3-32	6
204	Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. 2013 , 16, 1423-33	62
203	Role of antidiarrhoeal drugs as adjunctive therapies for acute diarrhoea in children. 2013 , 2013, 612403	22
202	Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. 2014 , 7, 345-58	22
201	Thoracic Epidural analgesia versus Rectus Sheath Catheters for open midline incisions in major abdominal surgery within an enhanced recovery programme (TERSC): study protocol for a randomised controlled trial. 2014 , 15, 400	19
200	Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity. 2014 , 5, 262	20
199	An in vitro rat model of colonic motility to determine the effect of Ecasomorphin-5 on propagating contractions. 2014 , 5, 2768-74	19
198	Spatiotemporal organization of standing postprandial contractions in the distal ileum of the anesthetized pig. <i>Neurogastroenterology and Motility</i> , 2014 , 26, 1651-62	4 11

197	Detection of drug effects on gastric emptying and contractility using a wireless motility capsule. 2014 , 14, 2		19
196	Protective effect of hydroalcoholic olive leaf extract on experimental model of colitis in rat: involvement of nitrergic and opioidergic systems. 2014 , 28, 1367-73		20
195	Effect of prolonged general anesthesia with sevoflurane and laparoscopic surgery on gastric and small bowel propulsive motility and pH in dogs. 2014 , 41, 73-81		30
194	Circular muscle contraction in the mice rectum plays a key role in morphine-induced constipation. <i>Neurogastroenterology and Motility</i> , 2014 , 26, 1396-407	4	21
193	Pharmacology of Opioids and their Effects on Gastrointestinal Function. 2014 , 2, 9-16		30
192	Pharmacologic treatments for esophageal disorders. 2014 , 1325, 23-39		8
191	Standardized treatment of Chinese medicine decoction for cancer pain patients with opioid-induced constipation: a multi-center prospective randomized controlled study. 2014 , 20, 496-502		10
190	Molecular physiology of enteric opioid receptors. 2014 , 2, 17-21		86
189	Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. 2014 , 49, 24-45		109
188	HIV, opiates, and enteric neuron dysfunction. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 449-54	4	11
187	Opioid-induced Lower Esophageal Sphincter Dysfunction. 2015 , 21, 618-20		23
186	The pharmacological basis of opioids. 2015 , 12, 219-21		61
185	Pharmacologic Agents for Chronic Diarrhea. 2015 , 13, 306-12		24
184	Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. 2015 , 9, 2215-31		48
183	Acetylcholine serves as a derepressor in Loperamide-induced Opioid-Induced Bowel Dysfunction (OIBD) in zebrafish. 2014 , 4, 5602		20
182	Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors. 2015 , 345-363		1
181	Evolving paradigms in the treatment of opioid-induced bowel dysfunction. 2015 , 8, 360-72		42
180	Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways. 2015 , 470, 155-67		14

179	Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids. 2015 , 110, 979-84		125
178	Opioid receptors and associated regulator of G protein signaling are involved in the cathartic colon of rats. 2015 , 9, 1229-1234		4
177	The impact of chronic opioid use on colonoscopy outcomes. 2015 , 60, 1016-23		6
176	Activation of μ opioid receptors modulates inflammation in acute experimental colitis. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 509-23	4	22
175	Opioid-induced constipation. 2015 , 50, 1331-8		19
174	Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids. 2015 , 6, e90		18
173	A Preliminary Study Examining Nutritional Risk Factors, Body Mass Index, and Treatment Retention in Opioid-Dependent Patients. 2015 , 42, 401-8		8
172	From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. 2015 , 29, 146-56		60
171	The Effect of DA-9701 in Opioid-induced Bowel Dysfunction of Guinea Pig. 2016 , 22, 529-38		8
170	The Impact of Opioid Treatment on Regional Gastrointestinal Transit. 2016 , 22, 282-91		37
169	Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. 2016 , 12, 771-5		11
168	Cissus sicyoides: Pharmacological Mechanisms Involved in the Anti-Inflammatory and Antidiarrheal Activities. 2016 , 17,		10
167	Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. 2016 , 7, 414		95
166	Management of chronic visceral pain. 2016 , 6, 469-86		19
165	The Enteric Nervous System. 2016 ,		
164	G Protein-Coupled Receptor Trafficking and Signalling in the Enteric Nervous System: The Past, Present and Future. 2016 , 891, 145-52		7
163	The effect of opioid agonists and antagonists on gastrointestinal motility in mice selected for high and low swim stress-induced analgesia. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 175-85	4	4
162	Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain. 2016 , 16, 985-993		20

161	Distribution and trafficking of the μ -opioid receptor in enteric neurons of the guinea pig. 2016 , 311, G252-66	17
160	Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. 2017 , 18, 1837-1863	82
159	Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. 2016 , 11, 111-122	57
158	Enteric Nervous System: Neuropathic Gastrointestinal Motility. 2016 , 61, 1803-16	14
157	Enhanced Sensitivity of $\alpha 4 \beta 2$ Nicotinic Receptors in Enteric Neurons after Long-Term Morphine: Implication for Opioid-Induced Constipation. 2016 , 357, 520-8	4
156	6EN-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand. 2016 , 7, 1120-9	9
155	Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 26-35	4 31
154	Neonatal abstinence syndrome and the gastrointestinal tract. 2016 , 97, 11-15	4
153	Opioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment. 2016 , 1, 25-35	13
152	Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. 2016 , 17, 1395-402	9
151	P2Y1, P2Y2, and TRPV1 Receptors Are Increased in Diarrhea-Predominant Irritable Bowel Syndrome and P2Y2 Correlates with Abdominal Pain. 2016 , 61, 2878-2886	14
150	Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3L and PAC-QOL. 2016 , 6, 14	12
149	Management of opioid-induced constipation. 2016 , 25, S4-5, S8-11	23
148	Opioid Analgesics. 2016 , 267-301	1
147	Opioid-induced functional esophagogastric junction obstruction. 2017 , 40, 296-298	4
146	Effect of the duration of food withholding prior to anesthesia on gastroesophageal reflux and regurgitation in healthy dogs undergoing elective orthopedic surgery. 2017 , 78, 144-150	12
145	Effect of methylnaltrexone and naloxone on esophageal motor function in man. <i>Neurogastroenterology and Motility</i> , 2017 , 29, e12938	4 9
144	Analgesia and mouse strain influence neuromuscular plasticity in inflamed intestine. <i>Neurogastroenterology and Motility</i> , 2017 , 29, 1-12	4 6

143	Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. 2017 , 15, 1338-1349	73
142	The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review. 2017 , 6, 1-16	23
141	Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. 2017 , 32, 77-84	103
140	6. Konzepte der Arzneimitteltherapie. 2017 ,	
139	Ultrasonographic gastric volume before unplanned surgery. 2017 , 72, 1112-1116	17
138	Opioid-induced functional esophagogastric junction obstruction. 2017 , 40, 296-298	
137	Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. 2017 , 18, 1496-1504	19
136	Mu and delta opioid receptor knockout mice show increased colonic sensitivity. 2017 , 21, 623-634	14
135	Analgesic Agents in Rheumatic Disease. 2017 , 1075-1095	0
134	Gastric Emptying. 2017 ,	1
133	Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective. 2017 , 109, 788-794	1
132	A concise review of opioid-induced esophageal dysfunction: is this a new clinical entity?. 2018 , 31,	13
131	Differential effect of morphine on gastrointestinal transit, colonic contractions and nerve-evoked relaxations in Toll-Like Receptor deficient mice. 2018 , 8, 5923	7
130	Influence of a single dose of buprenorphine on rabbit (<i>Oryctolagus cuniculus</i>) gastrointestinal motility. 2018 , 45, 510-519	11
129	Pathophysiology, diagnosis, and management of opioid-induced constipation. 2018 , 3, 203-212	40
128	An update on equine post-operative ileus: Definitions, pathophysiology and management. 2018 , 50, 292-303	14
127	Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13367	4 8
126	Pharmacology of Opioids. 2018 , 123-137	1

125	Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13250	4	5
124	Immunohistochemical identification of dynorphin A and Kappa opioid receptor-1 in the digestive system of scallop <i>Chlamys farreri</i> . 2018 , 36, 2288-2296		
123	A influência da morfina ou tramadol pela via epidural no trânsito gastrointestinal de equinos. 2018 , 70, 1477-1482		
122	Assessing the Efficacy of Maropitant Versus Ondansetron in the Treatment of Dogs with Parvoviral Enteritis. 2018 , 54, 338-343		4
121	Opioid-Induced Esophageal Dysfunction: An Emerging Entity with Sweeping Consequences. 2018 , 16, 616-621		4
120	Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?. 2018 , 43, 53-58		6
119	Neuropathophysiology of the Irritable Bowel Syndrome. 2018 , 1643-1668		2
118	Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350. 2018 , 24, 119-127		16
117	Methylation Products of 6βN-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators. 2018 , 9, 3028-3037		5
116	Post-operative Weaning of Opioids After Ambulatory Surgery: the Importance of Physician Stewardship. 2018 , 22, 40		13
115	Inflammation-associated changes in DOR expression and function in the mouse colon. 2018 , 315, G544-G559		15
114	μ-opioid receptor, δ-opioid receptor, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13688	4	15
113	[Emerging Issues in Esophageal Motility Diseases]. 2019 , 73, 322-326		1
112	Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone. 2019 , 25, 602-610		8
111	Itopride increases the effectiveness of the management of opioid-induced constipation in palliative care patients: an observational non-interventional study. 2019 ,		1
110	Opioids Preconditioning Upon Renal Function and Ischemia-Reperfusion Injury: A Narrative Review. 2019 , 55,		7
109	The Mechanisms Involved in Morphine Addiction: An Overview. 2019 , 20,		39
108	The Role of Opioids and Alcohol in the Development of Achalasia Type III and Esophagogastric Junction Outflow Obstruction. 2019 , 25, 177-178		1

107	Physiology of Electrolyte Transport in the Gut: Implications for Disease. 2019 , 9, 947-1023		15
106	Clathrin and GRK2/3 inhibitors block μ opioid receptor internalization in myenteric neurons and inhibit neuromuscular transmission in the mouse colon. 2019 , 317, G79-G89		4
105	Pharmacologic effects of naldemedine, a peripherally acting μ opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13563	4	15
104	Agonist-dependent development of delta opioid receptor tolerance in the colon. 2019 , 76, 3033-3050		5
103	Quantitative Systems Pharmacological Analysis of Drugs of Abuse Reveals the Pleiotropy of Their Targets and the Effector Role of mTORC1. 2019 , 10, 191		6
102	Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions. 2019 , 44, 361-371		5
101	Evaluation of In Vivo Antidiarrheal Activities of Hydroalcoholic Leaf Extract of L.(Sapindaceae) in Swiss Albino Mice. 2019 , 24, 2515690X19891952		9
100	Opioid-Induced Foregut Dysfunction. 2019 , 114, 1716-1725		7
99	Opioid-Induced Esophageal Dysfunction: Differential Effects of Type and Dose. 2019 , 114, 1464-1469		26
98	Weaning From Long-term Opioid Therapy. 2019 , 62, 98-109		5
97	Novel synthetic opioids: A review of the literature. 2019 , 31, 298-316		8
96	Colonic Electromechanical Abnormalities Underlying Post-operative Ileus: A Systematic and Critical Review. 2019 , 25, 36-47		8
95	Pathophysiology and management of opioid-induced constipation: European expert consensus statement. 2019 , 7, 7-20		52
94	Codeine delays gastric emptying through inhibition of gastric motility as assessed with a novel diagnostic intragastric balloon catheter. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13733	4	10
93	Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics. 2020 , 87, 15-21		44
92	Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13753	4	4
91	Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon. 2020 , 9, 465-483		12
90	Esophageal body motility disorders. 2020 , 195-211		

89	Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study. 2020 , 11, 576624	3
88	Toll-Like Receptor 4 (TLR4)/Opioid Receptor Pathway Crosstalk and Impact on Opioid Analgesia, Immune Function, and Gastrointestinal Motility. 2020 , 11, 1455	34
87	Stercoral Perforation in a Patient on Suboxone Treatment. 2020 , 61, 764-768	1
86	The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids. 2020 , 161, 2041-2057	1
85	Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. 2020 , 52, 37-53	7
84	Opioid-induced esophageal dysfunction. 2020 , 36, 344-350	5
83	Opioid use is associated with incomplete capsule endoscopy examinations: a systematic review and meta-analysis. 2020 , 5, 5	0
82	The Use of Peripheral μ Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety. 2020 , 14, 1009-1025	22
81	Evaluating naloxegol for the treatment of opioid-induced constipation. 2020 , 21, 883-891	2
80	Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study. 2020 , 28, 5315-5321	3
79	Other Uses of Morphine. 2020 ,	
78	Preventive effects of naldemedine, peripherally acting μ opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets. 2020 , 257, 118048	2
77	Chronic Methadone Use Alters the CD8 T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli. 2020 , 204, 1188-1200	4
76	The opioid-P2Y inhibitor interaction: Potential strategies to mitigate the interaction and consideration of alternative analgesic agents in myocardial infarction. 2021 , 217, 107665	3
75	Codeine induces increased resistance at the esophagogastric junction but has no effect on motility and bolus flow in the pharynx and upper esophageal sphincter in healthy volunteers: A randomized, double-blind, placebo-controlled, cross-over trial. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14041	4 3
74	Constipation. 2021 , 1229-1264	0
73	Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. 2021 , 48, 855-874	2
72	An atlas of neural crest lineages along the posterior developing zebrafish at single-cell resolution. 2021 , 10,	12

71	[Diagnosis of Dysphagia: High Resolution Manometry & EndoFLIP]. 2021 , 77, 64-70		2
70	Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel. 2021 , 38, 3589-3621		5
69	Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology. 2021 , 230, 107961		5
68	Biased Opioid Ligands: Revolution or Evolution?. 2021 , 2, 722820		0
67	Multiple Sclerosis and the Endogenous Opioid System. 2021 , 15, 741503		2
66	The Guts of the Opioid Crisis. 2021 , 36, 315-323		1
65	Chronic opioid use is associated with obstructive and spastic disorders in the esophagus. <i>Neurogastroenterology and Motility</i> , 2021 , e14233	4	0
64	Pathogenese, Prophylaxe und Therapie des postoperativen Ileus in der onkologischen Kolonchirurgie. 2021 , 349-363		
63	Physical Considerations for Treatment Complications of Alcohol and Drug Use and Misuse. 2010 , 1115-1145		1
62	Dysfunction of the Bowel/Constipation. 2012 , 221-244		1
61	Intestinal Electrolyte Absorption and Secretion. 2010 , 1675-1694.e3		3
60	An atlas of neural crest lineages along the posterior developing zebrafish at single-cell resolution.		1
59	Same-day opioid administration in opiate naïve patients is not associated with opioid-induced esophageal dysfunction (OIED). <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14059	4	5
58	<i>Nigella sativa</i> (black cumin) seed extract alleviates symptoms of allergic diarrhea in mice, involving opioid receptors. 2012 , 7, e39841		32
57	Opioid-induced mitogen-activated protein kinase signaling in rat enteric neurons following chronic morphine treatment. 2014 , 9, e110230		24
56	Chronic methadone use, poor bowel visualization and failed colonoscopy: a preliminary study. 2012 , 18, 4350-6		12
55	Pharmacological challenges in chronic pancreatitis. 2013 , 19, 7302-7		20
54	Neurochemical features of endomorphin-2-containing neurons in the submucosal plexus of the rat colon. 2015 , 21, 9936-44		4

53	Transcriptomic Analysis Reveals Receptor Subclass-Specific Immune Regulation of CD8 T Cells by Opioids. 2020 , 4, 420-429	1
52	Early Results of Fecal Microbial Transplantation Protocol Implementation at a Community-based University Hospital. 2018 , 10, 47-57	12
51	Drugs and Bugs: The Gut-Brain Axis and Substance Use Disorders. 2021 , 1	2
50	The effect of opioids on gastrointestinal function in the ICU. 2021 , 25, 370	3
49	Influence of dalargin on secretory function of liver. 2006 , 5, 21-25	1
48	The role of Opioid receptors in the regulation of hepatic secretory function. 2006 , 5, 90-95	
47	Intestinal Dysfunction and Obstruction. 2009 , 1267-1275	2
46	Molecular Modulation of In Vivo Tolerance. 2011 , 439-455	
45	Constipation. 2012 , 337-350	
44	Postoperative Schmerztherapie. 2012 , 1382-1431	1
43	Analgesic Agents in Rheumatic Disease. 2013 , 1014-1033.e3	
42	Postoperative Schmerztherapie: Neurophysiologische Aspekte von Schmerz. 2016 , 1-11	
41	Postoperative Schmerztherapie bei Kindern. 2016 , 1-9	
40	Postoperative Schmerztherapie bei ambulanten Patienten. 2016 , 1-3	
39	Postoperative Schmerztherapie: Regionale Analgesie. 2016 , 1-20	
38	Postoperative Schmerztherapie: Systemische Analgesie. 2016 , 1-17	
37	Postoperative Schmerztherapie bei opioidgewöhnten Patienten. 2016 , 1-6	
36	Postoperative Schmerztherapie: Grundlagen, Organisation und Ausblick. 2016 , 1-7	

- 35 Postoperative Schmerztherapie: Neurophysiologische Aspekte von Schmerz. **2018**, 1-10
- 34 Quantitative systems pharmacological analysis of drugs of abuse reveals the pleiotropy of their targets and the effector role of mTORC1.
- 33 Postoperative Schmerztherapie: Neurophysiologische Aspekte von Schmerz. **2019**, 1873-1881
- 32 Opioid Modulation of the Gut-Brain Axis in Opioid-Associated Comorbidities. **2021**, 11, o
- 31 Diseases of the Alimentary Tract. **2020**, 702-920.e35
- 30 Constipation. **2020**, 1-37
- 29 Opioidergic regulation of contractile activity of lymphatic vessels. **2020**, 19, 57-63
- 28 The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review. **2013**, 5, 5-16 35
- 27 New approaches to the treatment of opioid-induced constipation. **2008**, 12 Suppl 1, 119-27 14
- 26 Evidence of morphine like substance and Epioid receptor expression in (Nematoda: Ascaridae). **2016**, 7, 335-339 3
- 25 Naldemedine for the Use of Management of Opioid Induced Constipation. **2020**, 50, 97-118 o
- 24 Mechanistic overview of how opioid analgesics promote constipation. **2022**, 227-234
- 23 Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?. **2021**, 13, o
- 22 Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gut motility disorders. **2021**, 1
- 21 Chronic Morphine Induces IL-18 in Ileum Myenteric Plexus Neurons Through Mu-opioid Receptor Activation in Cholinergic and VIPergic Neurons.. **2022**, 1
- 20 The Involvement of the Endogenous Opioid System in the Gastrointestinal Aging in Mice and Humans.. **2022**, 23,
- 19 Clinical Features and Risk Factors for Gastrointestinal Complications in Dogs Treated Surgically for Thoracolumbar Intervertebral Disc Extrusion.. **2021**, 8, 785228 1
- 18 Table_1.docx. **2019**,

17 Table_2.XLSX. **2019**,

16 Table_3.XLSX. **2019**,

15 Table_4.XLSX. **2019**,

14 Table_5.XLSX. **2019**,

13 DataSheet_1.docx. **2020**,

12 Hypermobile Ehlers-Danlos Syndrome and disorders of the gastrointestinal tract. What the Gastroenterologist needs to know. ○

11 Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system. 13, 1

10 Bisacodyl overcomes morphine-induced constipation by decreasing colonic Aquaporin-3 and Aquaporin-4 expression. **2022**, 8, 65-75 ○

9 N-Terminally Lipidated Sialorphan AnalogsâSynthesis, Molecular Modeling, In Vitro Effect on Enkephalins Degradation by NEP and Treatment of Intestinal Inflammation in Mice. **2022**, 23, 14450 ○

8 Pharmacologic causes of dysphagia. **2023**, 141-160 ○

7 A Fentanyl Analogue That Activates u-Opioid Receptors in Acidified Tissues Inhibits Colitis Pain without Opioid Side Effects. **2023**, 143-152 ○

6 Pre-existing Opioid Use Worsens Outcomes in Patients With Diverticulitis. **2023**, ○

5 Double-blinded placebo-controlled clinical trial of prophylactic omeprazole in dogs treated surgically for acute thoracolumbar intervertebral disc extrusion. **2023**, 37, 586-597 ○

4 Effects of opium tincture on the enteric and central nervous systems: A randomized controlled trial. **2023**, 132, 434-448 ○

3 Opioids in the Treatment of Chronic Idiopathic Diarrhea in HumansâA Systematic Review and Treatment Guideline. **2023**, 12, 2488 ○

2 Diagnosis and Management of Opioid-Induced Esophageal Dysfunction. ○

1 Impact of opioids on esophageal motility. ○